(GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation today announced that, in December, it closed on the acquisition of the product portfolio from Metasurg.
The addition of the Metasurg product portfolio enhances Integra’s lower extremity product offering with easy to use implant systems. It also offers the opportunity to distribute a biologic allograft derived from human placental tissue as a possible complement to Integra’s wound care product offering.
Revenues in 2013 were approximately $6 million, with growth in the double digits over the prior year period. The Company expects minimal impact on profits in 2015 and slower growth during the transition period, before returning to double digit growth longer term.
Metasurg was founded in 2005 in Houston, TX, with the goal of providing foot and ankle surgeons intuitive, easy-to-use implant systems. The Company has commercialized a variety of implant systems, launching five products over the last several years. The acquired portfolio includes the DigiFuse ® Cannulated Intramedullary Fusion System, MemoFix ® Super Elastic Nitinol Staple System, Ti6® screw portfolio, BioMotion® 1st MPJ Hemi System and TruArch® Subtalar Implant System. In addition to these implants, the acquisition also offers Integra the opportunity to distribute an amniotic product line called BioFix ® Regenerative Biologics.
Source: Integra